Department of General Medicine, Christian Medical College, Vellore, India.
Department of Infectious Disease, Christian Medical College, Vellore, India.
J Vector Borne Dis. 2021 Jan-Mar;58(1):33-38. doi: 10.4103/0972-9062.321748.
Fever defervescence in scrub typhus, a zoonotic bacterial infection is used as a surrogate marker of disease resolution. Failure of fever defervescence prompts clinicians to suspect alternate diagnoses and treatment. In this observational study, various treatment regimens were correlated with clinical outcomes.
All adult patients with a diagnosed scrub typhus were included; various antibiotic regimens used and clinical outcomes were studied. Data was analyzed using SPSS software for windows 16, with a 2-sided P-value of 0.05 or less was considered statistically significant.
In 177 hospitalized patients with scrub typhus, combination therapy (doxycycline and azithromycin) was used in 74 subjects with doxycycline and azithromycin used in 46 and 57 subjects, respectively. Incidence of delayed defervescence was seen in 31.6%, Combination therapy being preferred in sicker patients (SOFA score 8.82). Presence of respiratory dysfunction was associated with a delay in fever defervescence [risk ratio 2.50(1.18-5.3)]. Patients receiving doxycycline did better in terms of oxygen requirement and the presence of hypotension. The overall case fatality rate was 5.6%. The severity of illness rather than the choice of antibiotics predicted the outcome in scrub typhus.
INTERPRETATION & CONCLUSION: Combination therapy with doxycycline and azithromycin is the most common regimen used. Incidence of delayed defervescence (31.6%) is increasing despite therapy and the involvement of respiratory dysfunction is an independent predictor of delayed fever defervescence.
恙虫病是一种人畜共患的细菌性传染病,退热可作为疾病痊愈的替代标志物。如果未能退热,临床医生会怀疑存在其他诊断和治疗方法。本观察性研究对各种治疗方案与临床结局的相关性进行了分析。
纳入所有诊断为恙虫病的成年患者;研究了各种抗生素方案的使用和临床结局。使用 Windows 16 版 SPSS 软件进行数据分析,双侧 P 值<0.05 被认为具有统计学意义。
在 177 例住院恙虫病患者中,74 例采用联合治疗(多西环素和阿奇霉素),46 例和 57 例分别采用多西环素和阿奇霉素。有 31.6%的患者出现退热延迟,联合治疗更常用于病情较重的患者(SOFA 评分 8.82)。存在呼吸功能障碍与发热延迟有关[风险比 2.50(1.18-5.3)]。接受多西环素治疗的患者在氧需求和低血压的发生率方面表现更好。总体病死率为 5.6%。恙虫病的预后是由疾病严重程度决定,而不是抗生素的选择。
多西环素联合阿奇霉素是最常用的治疗方案。尽管进行了治疗,但仍有 31.6%的患者出现退热延迟,呼吸功能障碍的存在是发热延迟的独立预测因素。